Bevacizumab in the treatment of ovarian cancer

Advances in Therapy

Volumn 29, Issue 9, 2012, Pages 723-735

  Heitz, Florian ^a   Harter, Philipp ^a   Barinoff, Jana ^a   Beutel, Bianca ^a   Kannisto, Paevi ^a   Grabowski, Jacek P ^a   Heitz, Julia ^a   Kurzeder, Christian ^a   Du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Antiangiogenic therapy; Bevacizumab; Carcinoma; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PLACEBO; TOPOTECAN; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84866479731     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0041-9     Document Type: Review

References (50)

1. Kober J. The reluctant surgeon. A biography of John Hunter. Garden City, New York: Doubleday & Company, Inc.; 1960.
2. Thiersch C. Der Epithelialkrebs namentlich der Haut mit Atlas. Leipzig: 1865.
3. Sandison J. The transparent chamber of the rabbits ear, giving a complete description of improved technic of construction and introduction, and general account of growth and behavior of living cells and tissues as seen with the microscope. Am J Anat. 1928;41:447-72.
4. Ide A, Baker N, Warren S, et al. Vascularization of the Brown-Pearce rabbit epitheioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939;42:891-9.
5. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-88.
6. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-8. (Pubitemid 19162712)
7. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9. (Pubitemid 27441066)
8. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
9. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-44.
10. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
11. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-9.
12. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-200. (Pubitemid 46606249)
13. Mahner S, Woelber L, Eulenburg C, et al. TIMP-1 and VEGF-165 serum concentration during first- line therapy of ovarian cancer patients. BMC Cancer. 2010;10:139.
14. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res. 2002;8:3193-7. (Pubitemid 35155030)
15. Gadducci A, Ferdeghini M, Fanucchi A, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19:1401-5. (Pubitemid 29257466)
16. Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 2008;14:7781-9.
17. du Bois A, Rochon J, Lamparter C, et al. Die Qualität der Therapie des Ovarialkarzinoms in Deutschland. Frauenarzt. 2009;50:742-51.
18. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154-9.
19. Brown JV III, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer. 2010;20:1132-36.
20. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17:771-6. (Pubitemid 47063333)
21. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29:4662-8.
22. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83.
23. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
24. AGO Study Group. Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST). ClinicalTrials no. NCT01462890. Available at: http://clinicaltrials.gov/ct2/show/NCT01462890. Accessed June 1 2012.
25. Heitz F, du Bois A, Kurzeder C, et al. Surgery for recurrent ovarian cancer. Womens Health (Lond Engl). 2011;7:529-35.
26. AGO Study group. Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOP III). (NCT01166737). Available at: http://clinicaltrials.gov/ct2/show/NCT01166737. Accessed July 1 2012.
27. GOG. Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer. (NCT00565851). Available at: http://clinicaltrials.gov/ct2/show/NCT00565851. Accessed July 1 2012.
28. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-5.
29. Meier W, du Bois A, Reuss A, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009;114:199-205.
30. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-18. (Pubitemid 47123191)
31. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-6. (Pubitemid 351398081)
32. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-93. (Pubitemid 27251118)
33. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-106.
34. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-707. (Pubitemid 46630933)
35. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-9.
36. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21:756-62.
37. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6. (Pubitemid 350232248)
38. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
39. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-71. (Pubitemid 350237599)
40. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107:326-30. (Pubitemid 47575735)
41. Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110:49-55.
42. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:578-84.
43. Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122:233-7.
44. Muggia FM, Boyd L, Liebes L, et al. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009;27 (Suppl.):15s (Abstract 5548).
45. McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study. Cancer. 2011;117:3731-40.
46. Del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinumsensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012;126:369-74.
47. Aghajanian C, Finkler N, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebocontrolled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2011;29 (Suppl.). Abstract LBA5007.
48. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl.). Abstract LBA5002.
49. Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol. 2011;29:1230-2.
50. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-51.